Altered Treg Infiltration after Discoidin Domain Receptor 1 (DDR1) Inhibition and Knockout Promotes Tumor Growth in Lung Adenocarcinoma.

discoidin domain receptor 1 non-small cell lung cancer regulatory T cells tumor microenvironment

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
08 Dec 2023
Historique:
received: 08 09 2023
revised: 20 11 2023
accepted: 29 11 2023
medline: 23 12 2023
pubmed: 23 12 2023
entrez: 23 12 2023
Statut: epublish

Résumé

Lung cancer is the leading cause of cancer-related death worldwide. Discoidin domain receptor 1 (DDR1), a tyrosine kinase receptor, has been associated with poor prognosis in patients with non-small cell lung cancer (NSCLC). However, its role in tumorigenesis remains poorly understood. This work aimed to explore the impact of DDR1 expression on immune cell infiltration in lung adenocarcinoma. Pharmacological inhibition and knockout of DDR1 were used in an immunocompetent mouse model of KRAS/p53-driven lung adenocarcinoma (LUAD). Tumor cells were engrafted subcutaneously, after which tumors were harvested for investigation of immune cell composition via flow cytometry. The Cancer Genome Atlas (TCGA) cohort was used to perform gene expression analysis of 509 patients with LUAD. Pharmacological inhibition and knockout of DDR1 increased the tumor burden, with DDR1 knockout tumors showing a decrease in CD8

Identifiants

pubmed: 38136314
pii: cancers15245767
doi: 10.3390/cancers15245767
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : FWF Austrian Science Fund
ID : P35294
Organisme : FWF Austrian Science Fund
ID : P33325
Organisme : FWF Austrian Science Fund
ID : KLI887
Organisme : FWF Austrian Science Fund
ID : W1241
Organisme : OENB Anniversary Fund
ID : 17584
Organisme : Austrian Research Promotion Agency
ID : 871284
Organisme : Austrian Academy of Sciences
ID : 26477

Auteurs

Kathrin Maitz (K)

Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, 8010 Graz, Austria.

Paulina Valadez-Cosmes (P)

Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, 8010 Graz, Austria.

Sofia Raftopoulou (S)

Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, 8010 Graz, Austria.

Oliver Kindler (O)

Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, 8010 Graz, Austria.

Melanie Kienzl (M)

Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, 8010 Graz, Austria.

Hamid Bolouri (H)

Center for Systems Immunology, Benaroya Research Center, Seattle, WA 98101, USA.
Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

A McGarry Houghton (AM)

Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA 98195, USA.

Rudolf Schicho (R)

Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, 8010 Graz, Austria.
BioTechMed, 8010 Graz, Austria.

Akos Heinemann (A)

Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, 8010 Graz, Austria.
BioTechMed, 8010 Graz, Austria.

Julia Kargl (J)

Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, 8010 Graz, Austria.
BioTechMed, 8010 Graz, Austria.

Classifications MeSH